Pasithea Therapeutics (KTTA) Return on Equity (2021 - 2024)
Historic Return on Equity for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to 0.63%.
- Pasithea Therapeutics' Return on Equity fell 5900.0% to 0.63% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.63%, marking a year-over-year decrease of 5900.0%. This contributed to the annual value of 0.01% for FY2023, which is 300.0% up from last year.
- According to the latest figures from Q3 2024, Pasithea Therapeutics' Return on Equity is 0.63%, which was down 5900.0% from 0.43% recorded in Q2 2024.
- In the past 5 years, Pasithea Therapeutics' Return on Equity registered a high of 0.01% during Q3 2022, and its lowest value of 0.63% during Q3 2024.
- For the 4-year period, Pasithea Therapeutics' Return on Equity averaged around 0.13%, with its median value being 0.05% (2022).
- As far as peak fluctuations go, Pasithea Therapeutics' Return on Equity soared by 300bps in 2023, and later plummeted by -5900bps in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Return on Equity stood at 0.06% in 2021, then increased by 21bps to 0.05% in 2022, then surged by 65bps to 0.02% in 2023, then crashed by -3505bps to 0.63% in 2024.
- Its Return on Equity stands at 0.63% for Q3 2024, versus 0.43% for Q2 2024 and 0.19% for Q1 2024.